Publication date: Jun 01, 2025
The newly initiated study is a randomized, placebo-controlled trial consisting of 200 patients with Long COVID who have cognitive impairment sequelae and fatigue for at least 3 months. Rebound effect, referring to clinical and/or radiological worsening of disease activity, is a well-documented concern with certain disease-modifying therapies for MS, particularly when they are discontinued or switched. Efgartigimod, originally approved for myasthenia gravis, became the first and only neonatal Fc receptor (FcRn) blocker approved for the treatment of CIDP in 2024. While relapse rates were slightly higher among women, these findings were consistent with previously reported rates. WATCH TIME: 4 minutesWelcome to this special edition of Neurology News Network. Thanks for watching.
| Concepts | Keywords |
|---|---|
| Daybreak | Address |
| Insulin | Covid |
| Recruitment | Efgartigimod |
| Sclerosis | Initiated |
| Ivig | |
| Lc | |
| Long | |
| Ozanimod | |
| Phase | |
| Rebound | |
| Testing | |
| Transition | |
| Treatment | |
| Trial | |
| Worsening |
Semantics
| Type | Source | Name |
|---|---|---|
| drug | DRUGBANK | Tropicamide |
| disease | MESH | myasthenia gravis |
| disease | MESH | CIDP |
| disease | MESH | polyneuropathy |
| disease | MESH | sequelae |
| disease | MESH | cognitive impairment |
| disease | MESH | Long COVID |
| drug | DRUGBANK | Immune Globulin Human |
| drug | DRUGBANK | Ozanimod |
| drug | DRUGBANK | Coenzyme M |
| drug | DRUGBANK | Gadolinium |
| disease | MESH | multiple sclerosis |
| disease | MESH | relapse |